Literature DB >> 7540571

Interferon expression in the pancreases of patients with type I diabetes.

X Huang1, J Yuang, A Goddard, A Foulis, R F James, A Lernmark, R Pujol-Borrell, A Rabinovitch, N Somoza, T A Stewart.   

Abstract

We have used a reverse transcriptase-polymerase chain reaction (RT-PCR) protocol to examine the expression of cytokines in the pancreases and islets of patients with type I diabetes. We detect a significant increase in the level of expression of interferon (IFN)-alpha in the pancreases of the diabetic patients as compared with the control pancreases. In contrast, IFN-beta was detected at comparable levels in both groups, while IFN-gamma was detected in three of four control pancreases and one of four pancreases from the diabetic individuals. The IFN-alpha cDNAs generated by the RT-PCR were cloned and sequenced to determine which alpha-subtypes were being expressed. We found that the repertoire of subtypes was quite limited in any one individual (diabetic or not), although each individual was different with respect to the pattern of subtypes expressed. We also examined these pancreases for the expression of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, IL-2, IL-4, and IL-6. We found no detectable expression of TNF-alpha or IL-2 in any pancreases, and the expression of the other cytokines was variable, with no pattern emerging from the comparison of the diabetic and nondiabetic individuals. We conclude that, of the cytokines examined, only IFN-alpha was significantly increased in the diabetic patients, a result that is consistent with the possibility that this cytokine is directly involved in the development of type I diabetes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540571     DOI: 10.2337/diab.44.6.658

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  83 in total

Review 1.  Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease.

Authors:  S T Azar; H Tamim; H N Beyhum; M Z Habbal; W Y Almawi
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  Persistent infection of human pancreatic islets by coxsackievirus B is associated with alpha interferon synthesis in beta cells.

Authors:  W Chehadeh; J Kerr-Conte; F Pattou; G Alm; J Lefebvre; P Wattré; D Hober
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  STAT1 deficiency unexpectedly and markedly exacerbates the pathophysiological actions of IFN-alpha in the central nervous system.

Authors:  Jianping Wang; Robert D Schreiber; Iain L Campbell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-02       Impact factor: 11.205

Review 4.  Prospects for the prevention and reversal of type 1 diabetes mellitus.

Authors:  Nikolai Petrovsky; Diego Silva; Desmond A Schatz
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Pathogenesis of type 1 diabetes mellitus: interplay between enterovirus and host.

Authors:  Didier Hober; Pierre Sauter
Journal:  Nat Rev Endocrinol       Date:  2010-03-30       Impact factor: 43.330

6.  Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.

Authors:  T C T M van der Pouw Kraan; C A Wijbrandts; L G M van Baarsen; A E Voskuyl; F Rustenburg; J M Baggen; S M Ibrahim; M Fero; B A C Dijkmans; P P Tak; C L Verweij
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

Review 7.  Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.

Authors:  Xiaolun Huang; Daniel J Moore; Robert J Ketchum; Craig S Nunemaker; Boris Kovatchev; Anthony L McCall; Kenneth L Brayman
Journal:  Endocr Rev       Date:  2008-07-29       Impact factor: 19.871

8.  Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis.

Authors:  A Imagawa; N Itoh; T Hanafusa; M Waguri; M Kuwajima; Y Matsuzawa
Journal:  Diabetologia       Date:  1996-01       Impact factor: 10.122

Review 9.  Targeting Innate Immunity for Type 1 Diabetes Prevention.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

10.  Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil.

Authors:  D Maksimovic-Ivanic; V Trajkovic; D J Miljkovic; M Mostarica Stojkovic; S Stosic-Grujicic
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.